Simvastatin significantly reduces RhoA activity, accompanied by the reduced cell migration, cell proliferation, and malignancy of ccRCC cells, thus suggesting the effectiveness of simvastatin in ccRCC treatment. The gene discussed is RHOA; the disease is nonpapillary renal cell carcinoma.